These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inflammatory reactions in the pathogenesis of atherosclerosis. Fan J, Watanabe T. J Atheroscler Thromb; 2003 Feb; 10(2):63-71. PubMed ID: 12740479 [Abstract] [Full Text] [Related]
23. Lipid markers for atherosclerosis. Kottke BA. Am J Cardiol; 1986 Feb 12; 57(5):11C-17C. PubMed ID: 3080862 [Abstract] [Full Text] [Related]
24. Lipoprotein metabolism and atherogenesis: implications for therapy. Kostner GM. Cardiology; 1991 Feb 12; 78(3):194-201. PubMed ID: 1651161 [Abstract] [Full Text] [Related]
25. Role of VLDL receptor in atherogenesis. Takahashi S. Curr Opin Lipidol; 2021 Aug 01; 32(4):219-225. PubMed ID: 34227576 [Abstract] [Full Text] [Related]
26. An overview of atherosclerosis: a look to the future. Getz GS. Toxicol Pathol; 1990 Aug 01; 18(4 Pt 1):623-35. PubMed ID: 2091240 [Abstract] [Full Text] [Related]
27. Role of lipoprotein peroxidation in the pathogenesis of atherosclerosis. Steinbrecher UP. Clin Cardiol; 1991 Nov 01; 14(11):865-7. PubMed ID: 1764821 [Abstract] [Full Text] [Related]
28. [Gene polymorphisms in atherosclerotic diseases and lipoprotein metabolism disorders]. Yokode M. Nihon Ronen Igakkai Zasshi; 1999 Apr 01; 36(4):238-41. PubMed ID: 10410565 [Abstract] [Full Text] [Related]
29. Macrophage death and the role of apoptosis in human atherosclerosis. Hegyi L, Hardwick SJ, Siow RC, Skepper JN. J Hematother Stem Cell Res; 2001 Feb 01; 10(1):27-42. PubMed ID: 11276357 [Abstract] [Full Text] [Related]
30. Lipoprotein-matrix interactions in macrovascular disease in diabetes. Tannock LR, Chait A. Front Biosci; 2004 May 01; 9():1728-42. PubMed ID: 14977582 [Abstract] [Full Text] [Related]
31. Pathophysiology of atherosclerosis. Chobanian AV. Am J Cardiol; 1992 Nov 27; 70(17):3G-7G. PubMed ID: 1449096 [Abstract] [Full Text] [Related]
32. The process of atherogenesis--cellular and molecular interaction: from experimental animal models to humans. Ross R, Agius L. Diabetologia; 1992 Dec 27; 35 Suppl 2():S34-40. PubMed ID: 1478376 [Abstract] [Full Text] [Related]
33. A unifying theory of atherogenesis. Sloop GD. Med Hypotheses; 1996 Oct 27; 47(4):321-5. PubMed ID: 8910882 [Abstract] [Full Text] [Related]
34. Lp(a)--an atherogenic risk factor in human serum? Gries A, Kostner GM. Z Med Lab Diagn; 1990 Oct 27; 31(7):355-60. PubMed ID: 2151151 [No Abstract] [Full Text] [Related]
35. Remnant lipoproteins and atherogenesis. Kawakami A, Yoshida M, Tanaka A, Nakajima K, Yasukochi Y, Shimokado K, Numano F. Ann N Y Acad Sci; 2001 Dec 27; 947():366-9. PubMed ID: 11795292 [Abstract] [Full Text] [Related]
36. [The mysteries of lipoprotein (a): a bridge between thrombosis and atheroma]. Hachulla E, Parra HJ. Rev Med Interne; 1991 Dec 27; 12(3):192-7. PubMed ID: 1896711 [Abstract] [Full Text] [Related]
37. Do vascular wall cytokines promote atherogenesis? Libby P. Hosp Pract (Off Ed); 1992 Oct 15; 27(10):51-8. PubMed ID: 1400673 [Abstract] [Full Text] [Related]
38. [Relationship between atherosclerosis and the aging process]. Kuzuya F. Nihon Ronen Igakkai Zasshi; 1990 Jan 15; 27(1):1-6. PubMed ID: 2191160 [Abstract] [Full Text] [Related]
39. A stochastic process approach to the development of atheroma. Descovich GC, Gaddi A, Pallotti G, Pettazzoni P, Slawomirski MR. Med Hypotheses; 1987 Jul 15; 23(3):277-85. PubMed ID: 3614019 [Abstract] [Full Text] [Related]